Claritev（CTEV）株式概要
クラリテブ・コーポレーションは、その子会社とともに、米国の医療業界にデータ分析とテクノロジーを駆使したエンド・ツー・エンドのコスト管理、支払い、収益管理ソリューションを提供している。 詳細
CTEV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Claritev Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$30.12 |
| 52週高値 | US$74.07 |
| 52週安値 | US$11.50 |
| ベータ | 0.70 |
| 1ヶ月の変化 | 2.38% |
| 3ヶ月変化 | 41.81% |
| 1年変化 | -29.77% |
| 3年間の変化 | -61.97% |
| 5年間の変化 | -90.38% |
| IPOからの変化 | -92.25% |
最新ニュース
ナラティブ更新 • Jul 09
CTEV: Early FY26 Contract Wins Will Support Future Customer Expansion
Analysts have lowered the Claritev fair value estimate from $86 to $61, reflecting updated assumptions around profit margins and a higher future P/E. They also highlight ongoing efforts to grow contract wins, expand the customer base, and support a return to growth.
ナラティブ更新 • Jun 25
CTEV: New Contracts And Management Changes Will Support Future Upside Potential
Analysts have trimmed their average price target on Claritev to $61, reflecting a reset from prior expectations near $90. The revised target continues to be associated with support from new coverage initiations, recent management efforts, and recent contract wins cited across recent research.ナラティブ更新 • Jun 11
CTEV: New Contracts And Management Changes Will Drive Future Upside Potential
Claritev's updated analyst price target has moved lower by about $3 to $36.83, as analysts factor in slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple. This is partly offset by higher projected profit margins and recent Street targets that range from $32 to $61.Recent updates
ナラティブ更新 • Jul 09
CTEV: Early FY26 Contract Wins Will Support Future Customer Expansion
Analysts have lowered the Claritev fair value estimate from $86 to $61, reflecting updated assumptions around profit margins and a higher future P/E. They also highlight ongoing efforts to grow contract wins, expand the customer base, and support a return to growth.ナラティブ更新 • Jun 25
CTEV: New Contracts And Management Changes Will Support Future Upside Potential
Analysts have trimmed their average price target on Claritev to $61, reflecting a reset from prior expectations near $90. The revised target continues to be associated with support from new coverage initiations, recent management efforts, and recent contract wins cited across recent research.ナラティブ更新 • Jun 11
CTEV: New Contracts And Management Changes Will Drive Future Upside Potential
Claritev's updated analyst price target has moved lower by about $3 to $36.83, as analysts factor in slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple. This is partly offset by higher projected profit margins and recent Street targets that range from $32 to $61.
ナラティブ更新 • May 27
CTEV: Early FY26 Contracts And DOJ Probe Will Shape Execution Outlook
Analysts have lifted their Claritev price target to $40 from $21, pointing to stronger early FY26 contract wins and new customer additions as key drivers behind the updated fair value estimate of $22 and a higher future P/E assumption. Analyst Commentary Recent research points to improving sentiment around Claritev, with analysts highlighting early FY26 contract wins of US$44m in annual contract value and six new customer additions as key supports for the higher fair value estimate and revised P/E assumption behind the US$40 price target.ナラティブ更新 • May 05
CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside
Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.Seeking Alpha • Apr 20
Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)
Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking Alphaナラティブ更新 • Apr 20
CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside
Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.ナラティブ更新 • Apr 05
CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power
Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.ナラティブ更新 • Mar 22
CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins
Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.ナラティブ更新 • Mar 07
CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside
The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.ナラティブ更新 • Feb 21
CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins
Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.ナラティブ更新 • Feb 06
CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside
Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.ナラティブ更新 • Jan 23
CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins
Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.分析記事 • Jan 18
Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...ナラティブ更新 • Jan 09
CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside
Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.ナラティブ更新 • Dec 25
CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins
Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.ナラティブ更新 • Dec 11
CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion
Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.ナラティブ更新 • Nov 27
CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength
Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.ナラティブ更新 • Nov 06
CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026
Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.分析記事 • Nov 01
Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...ナラティブ更新 • Oct 23
Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments
Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.分析記事 • Sep 09
Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...ナラティブ更新 • Aug 08
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.分析記事 • Jul 30
Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jul 09
Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...新しいナラティブ • May 30
AI And Global Partnerships Will Reshape Personalized Medicine
AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.分析記事 • May 15
Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth
Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...分析記事 • Mar 20
Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding
Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...分析記事 • Feb 03
There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise
MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...分析記事 • Dec 20
MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...分析記事 • Dec 13
Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Oct 20
MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth
MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...分析記事 • Aug 18
MultiPlan Corporation (NYSE:MPLN) Not Doing Enough For Some Investors As Its Shares Slump 40%
To the annoyance of some shareholders, MultiPlan Corporation ( NYSE:MPLN ) shares are down a considerable 40% in the...株主還元
| CTEV | US Healthcare Services | US 市場 | |
|---|---|---|---|
| 7D | 0.9% | -1.2% | -1.4% |
| 1Y | -29.8% | -35.5% | 17.4% |
業界別リターン: CTEV過去 1 年間で-35.5 % の収益を上げたUS Healthcare Services業界を上回りました。
リターン対市場: CTEVは、過去 1 年間で17.4 % のリターンを上げたUS市場を下回りました。
価格変動
| CTEV volatility | |
|---|---|
| CTEV Average Weekly Movement | 20.2% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CTEVの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: CTEVの weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1980 | 3,000 | Travis Dalton | www.claritev.com |
クラリテブ・コーポレーション（Claritev Corporation）は、その子会社とともに、米国の医療業界にデータ分析とテクノロジーを駆使したエンド・ツー・エンドのコスト管理、支払い、収益管理ソリューションを提供している。同社は、参照ベースの価格設定、交渉サービス、不意打ち請求サービス、Vistaraなどのクレーム・インテリジェンス・ソリューション、プライマリ・ネットワーク、補完ネットワーク、ネットワーク構築・ネットワーク管理サービスなどのネットワーク・ソリューション、クリニカル・ネゴシエーション、プレペイメント・インテグリティ、ポストペイメント・インテグリティ、レベニュー・インテグリティ・サービスから成る支払い・レベニュー・インテグリティ・ソリューションを提供している。また、PlanOptix、CompleteVue、BenInsights、リスクスコア、補足的キャリアサービスから成るデータおよび分析ソリューションも提供している。同社は民間医療保険会社、第三者機関管理者、雇用主、ブローカー/コンサルタント、プロバイダー、政府系医療保険会社、システム・インテグレーターにソリューションを提供している。全国および地域の保険会社、ブルークロスおよびブルーシールドプラン、プロバイダー主催および独立系ヘルスプラン、TPA、損害保険会社、請求審査会社、その他請求審査プロセスに関わる企業にサービスを提供している。同社は以前はMultiPlan Corporationとして知られていたが、2025年2月にClaritev Corporationに社名を変更した。クラリテブ・コーポレーションは1980年に設立され、バージニア州マクリーンに本社を置いている。
Claritev Corporation 基礎のまとめ
| CTEV 基礎統計学 | |
|---|---|
| 時価総額 | US$518.08m |
| 収益（TTM） | -US$286.52m |
| 売上高(TTM) | US$978.76m |
0.5x
P/Sレシオ-1.8x
PER（株価収益率CTEV は割高か？
公正価値と評価分析を参照収益と収入
| CTEV 損益計算書（TTM） | |
|---|---|
| 収益 | US$978.76m |
| 売上原価 | US$262.06m |
| 売上総利益 | US$716.71m |
| その他の費用 | US$1.00b |
| 収益 | -US$286.52m |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 07, 2026
| 一株当たり利益（EPS） | -16.81 |
| グロス・マージン | 73.23% |
| 純利益率 | -29.27% |
| 有利子負債／自己資本比率 | -2,012.5% |
CTEV の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/20 23:02 |
| 終値 | 2026/07/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Claritev Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Steven Valiquette | Barclays |
| Glen Santangelo | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |